[Drugs in the Developmental Stage (Psychotropics)].

Drug development increasingly targets multiple diseases with a single compound, as seen with pimavanserin and psilocybin. Despite major pharmaceutical companies withdrawing from central nervous system drug development, research into drugs with novel mechanisms of action has advanced, marking a new era in clinical psychopharmacology.

Study at a glance

Abstract

In recent years, it is common for a single drug to be developed for multiple diseases almost simultaneously, e.g., pimavanserin and psilocybin. Although there was gloomy news for the field of neuropsychopharmacology, such as withdrawal of the world's leading mega-pharmaceutical companies from the development of CNS drugs, drugs based on novel mechanisms of action have been investigated. This is a new dawn in the field of clinical psychopharmacology.